Roche has reported positive results from the Phase III (APHINITY) clinical trial of perjeta (pertuzumab) in combination with herceptin (trastuzumab) and chemotherapy for the treatment of patients with breast cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The trial was conducted in collaboration with the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS).

Perjeta is being developed to target the HER2 receptor protein that is found outside the cancer cells in HER2-positive patients.

It is designed to inhibit the HER2 receptor from pairing with other HER receptors such as EGFR / HER1, HER3 and HER4 on the surface of cells.

See Also:

The trial results indicated that the drug has met its primary endpoint, and the adjuvant after surgery treatment resulted in a statistically significant decrease in the risk of recurrence or death when compared to herceptin and chemotherapy alone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The international, randomised, double-blind, placebo-controlled, two-arm Phase III trial evaluated the efficacy and safety of the combination therapy in 4,805 subjects with operable HER2-positive eBC.

"These results from the positive APHINITY study represent an important addition to the body of data for perjeta in the treatment of people with HER2-positive early breast cancer."

Roche chief medical officer and global product development head Sandra Horning said: “These results from the positive APHINITY study represent an important addition to the body of data for perjeta in the treatment of people with HER2-positive early breast cancer."

The secondary endpoints of the trial were cardiac and overall safety, overall survival, disease-free survival and health-related quality of life.

The safety profile of the perjeta-based regimen was found to be consistent with the previous studies and no new safety signals were identified.

The therapy is currently licenced for before surgery treatment of patients with HER2-positive eBC in more than 75 countries.

Image: Roche facility in Basel, Switzerland. Photo: courtesy of F Hoffmann-La Roche.